Biocon Group chairperson Kiran Mazumdar-Shaw predicts FY26 as a growth year, fueled by biosimilars, generics, and research ...

Kiran Mazumdar-Shaw suggestion was met with a flurry of responses, with many users pushing back against the idea.

Kiran Mazumdar-Shaw discusses the impact of US drug price reduction efforts on Indian pharma, Biocon's US expansion, strong ...

the board was of the opinion that we should look at other strategic options which also be includes evaluating a merger," Kiran Mazumdar-Shaw, chairperson, Biocon Group, told investors in an ...

Biosimilars, too, are expected to gain ground as healthcare systems worldwide look for cost-effective alternatives to ...

Kiran Mazumdar-Shaw urges India to unlock its trillion-dollar orange economy potential by 2047 through tech-driven ...

Biocon founder and global business leader Kiran Mazumdar Shaw has set an ambitious vision for India’s media and entertainment ...

The Chairperson of Biocon Group said that generics and biosimilars are clearly part of the Affordable Care Act, but they are not the target of President Trump's current efforts.

The biosimilars business accounted for 58% of Biocon's overall revenue in FY25. Biocon Biologics had said it would likely ...

Biotech firm Biocon on Thursday said its consolidated net profit surged over two-fold to Rs 344 crore in the fourth quarter ...

Bengaluru: Biocon, an Indian biopharmaceutical company, has reported a more than twofold increase in its fourth-quarter ...

Shaw highlighted the importance of elevating this sector in line with Prime Minister Narendra Modi’s vision of a globally ...